Zhou et al. [37] reported a greater apoptotic rate (36.88%) when breast cancer cells were treated with an MSNP co-delivery system of doxorubicin and BCL2 siRNA, when compared with approximately 14% of apoptotic cells observed for the group treated with only doxorubicin loaded in the delivery system. The gene discussed is BCL2; the disease is breast carcinoma.